About this trial

To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).

Eligibility criteria

Qualifiers

1. Diagnosed with hyperparathyroidism (primary, secondary, or tertiary), biochemically confirmed (e.g., serum calcium and/or intact PTH consistent with the underlying etiology), and undergoing clinically indicated management

Female and male patients

Age ≥ 18 years

Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Disqualifiers

Patients with a history of cervicofacial irradiation.

Patients currently taking lithium or with a history of lithium use.

Pregnant patients

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

1
Washington University School of Medicine63110, St LouisMissouri, United States

Sponsors and collaborators

Washington University School of Medicine

Lead sponsor